Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Researchers from The Second Hospital and Yuying Children’s Hospital of Wenzhou Medical University have published results of the preclinical characterization of a novel curcumin analogue, CP-41, being developed as a potential anticancer agent.
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
Quanta Therapeutics Inc. has announced progression of its pipeline of KRAS-directed drug candidates, with the receipt of IND approval from the FDA for QTX-3034.
The Congress of the European Society of Medical Oncology (ESMO) held in Madrid from Oct. 20 to 24, 2023, could well add the letter W to its acronym after the four sessions on gynecological cancer that could represent a milestone in the lives of all women who suffer from cervical, ovarian, or endometrial cancer.
China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have jointly developed aza-phenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody.
About two months ahead of the planned PDUFA date, the U.S. FDA has granted expanded approval of PD-1 antibody Jemperli (dostarlimab) from partners Anaptysbio Inc. and GSK plc for use in combination with standard-of-care chemotherapy. GSK said the drug would be the only frontline immuno-oncology treatment for endometrial cancer available in combination with carboplatin and paclitaxel. The supporting supplemental BLA for the expanded indication previously received priority review.
At the recent ASCO meeting, researchers from the University of Rochester reported preclinical data for on a new small-molecule inhibitor of WAP four-disulfide core domain protein 2 (HE4) – UR-238 – that is being investigated for the treatment of cancer.
Researchers at China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have divulged azaphenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
